NO20044964L - Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet - Google Patents

Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet

Info

Publication number
NO20044964L
NO20044964L NO20044964A NO20044964A NO20044964L NO 20044964 L NO20044964 L NO 20044964L NO 20044964 A NO20044964 A NO 20044964A NO 20044964 A NO20044964 A NO 20044964A NO 20044964 L NO20044964 L NO 20044964L
Authority
NO
Norway
Prior art keywords
prepared
pharmaceutical composition
preparation
camptothecin derivative
lyophilizing
Prior art date
Application number
NO20044964A
Other languages
English (en)
Norwegian (no)
Inventor
Takahiro Lto
Shinji Narisawa
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of NO20044964L publication Critical patent/NO20044964L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20044964A 2002-04-16 2004-11-15 Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet NO20044964L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002112864 2002-04-16
PCT/JP2003/004745 WO2003086471A2 (en) 2002-04-16 2003-04-15 Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin

Publications (1)

Publication Number Publication Date
NO20044964L true NO20044964L (no) 2004-11-15

Family

ID=29243336

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044964A NO20044964L (no) 2002-04-16 2004-11-15 Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet

Country Status (21)

Country Link
US (1) US20050215485A1 (sr)
EP (1) EP1501549A2 (sr)
JP (1) JP3927954B2 (sr)
KR (1) KR100700963B1 (sr)
CN (1) CN100544769C (sr)
AR (1) AR039272A1 (sr)
AU (1) AU2003223120B2 (sr)
BR (1) BR0309283A (sr)
CA (1) CA2480425A1 (sr)
HR (1) HRP20040894A2 (sr)
ME (1) MEP31308A (sr)
MX (1) MXPA04010178A (sr)
MY (1) MY136696A (sr)
NO (1) NO20044964L (sr)
PL (1) PL371677A1 (sr)
RS (1) RS91204A (sr)
RU (1) RU2315623C2 (sr)
TW (1) TW200306314A (sr)
UA (1) UA77295C2 (sr)
WO (1) WO2003086471A2 (sr)
ZA (1) ZA200408008B (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080242691A1 (en) * 2004-02-13 2008-10-02 Kabushiki Kaisha Yakult Honsha Aqueous Solution Preparation Containing Camptothecins
AU2005244768B2 (en) 2004-04-27 2011-06-09 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
AU2006270297B2 (en) 2005-07-14 2013-01-17 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
JP2007260275A (ja) * 2006-03-29 2007-10-11 Transcutaneous Technologies Inc イオントフォレーシス装置及びイオントフォレーシス投与用組成物
TWI505834B (zh) 2009-06-22 2015-11-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型5及8莢膜多醣結合物之免疫原性組合物之方法
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
CN102764260B (zh) * 2011-04-30 2014-07-30 正大天晴药业集团股份有限公司 一种喜树碱衍生物的药物组合物及其制备方法
WO2013011598A1 (ja) * 2011-07-15 2013-01-24 コニカミノルタホールディングス株式会社 溶解助剤を利用したリポソーム含有製剤およびその製造方法
CN113304278A (zh) 2014-12-26 2021-08-27 日本化药株式会社 喜树碱类高分子衍生物的药物制剂
KR20180039628A (ko) * 2015-09-03 2018-04-18 니폰 가야꾸 가부시끼가이샤 캄프토테신류 고분자 유도체를 함유하는 의약 조성물
WO2017053920A1 (en) 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
EP3424513A4 (en) * 2016-03-01 2019-10-23 Nippon Kayaku Kabushiki Kaisha PHARMACEUTICAL PREPARATION WITH CAMPTOTHECINOUS POLYMER DERIVATIVE
CN109481691A (zh) * 2018-11-20 2019-03-19 珠海天香苑生物科技发展股份有限公司 吉西他滨-羧甲基多糖共轭物、制备方法及其用途
EP4438062A1 (en) * 2021-11-26 2024-10-02 Astellas Pharma Inc. Indocyanine compound-containing solid pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340817A (en) * 1987-04-14 1994-08-23 Research Triangle Institute Method of treating tumors with anti-tumor effective camptothecin compounds
ATE136898T1 (de) * 1991-10-29 1996-05-15 Glaxo Wellcome Inc Wasserlösliche camptothecinderivate
SG50747A1 (en) * 1995-08-02 1998-07-20 Tanabe Seiyaku Co Comptothecin derivatives
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali
TW527183B (en) * 1996-06-06 2003-04-11 Daiichi Seiyaku Co Drug complex
US6288072B1 (en) * 1999-12-29 2001-09-11 Monroe E. Wall Camptothecin β-alanine esters with topoisomerase I inhibition
AR030207A1 (es) * 2000-04-07 2003-08-13 Daiichi Seiyaku Co Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma
BR0112417A (pt) * 2000-07-13 2003-07-01 Daiichi Seiyaku Co Composições farmacêuticas contendo composto dds
TWI313609B (en) * 2001-08-21 2009-08-21 Mitsubishi Tanabe Pharma Corp Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor

Also Published As

Publication number Publication date
JP2005523329A (ja) 2005-08-04
BR0309283A (pt) 2005-02-15
EP1501549A2 (en) 2005-02-02
RU2315623C2 (ru) 2008-01-27
PL371677A1 (en) 2005-06-27
CN100544769C (zh) 2009-09-30
MY136696A (en) 2008-11-28
CA2480425A1 (en) 2003-10-23
TW200306314A (en) 2003-11-16
RS91204A (sr) 2006-12-15
UA77295C2 (en) 2006-11-15
CN1646172A (zh) 2005-07-27
WO2003086471A2 (en) 2003-10-23
AR039272A1 (es) 2005-02-16
KR100700963B1 (ko) 2007-03-28
US20050215485A1 (en) 2005-09-29
MXPA04010178A (es) 2005-06-08
MEP31308A (en) 2010-10-10
HRP20040894A2 (en) 2005-10-31
ZA200408008B (en) 2005-06-13
AU2003223120A2 (en) 2003-10-27
JP3927954B2 (ja) 2007-06-13
RU2004133349A (ru) 2005-05-27
KR20050000516A (ko) 2005-01-05
AU2003223120A1 (en) 2003-10-27
WO2003086471A3 (en) 2004-04-15
AU2003223120B2 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
NO20044964L (no) Flytende preparat som omfatter camptothecinderivat og farmasoytisk preparat som kan fremstilles ved a lyofilisere preparatet
EP0513543B1 (de) Amidinophenylalaninderivate, Verfahren zu deren Herstellung, deren Verwendung und diese enthaltende Mittel als Antikoagulantien
EP0781781A3 (en) Camptothecin derivatives
PT1227806E (pt) Formulacao farmaceutica contendo tolterodina e sua utilizacao
MY116665A (en) Camptothecin derivatives
KR910002895A (ko) 펩티딜 아미노디올 레닌 억제제
CN109562064A (zh) 包含人胰高血糖素和统计共聚氨基酸的可注射水溶液形式的组合物
NO963464L (no) Nye opioidpeptider for behandling av smerte og anvendelse derav
JPS62500871A (ja) 薬理活性を有するジペプチド化合物及びそれを含む組成物
ZA200004680B (en) Certain thiol inhibitors of endothelin-converting enzyme.
EP1485345B1 (de) Hemmstoffe der urokinase, ihre herstellung und verwendung
KR102335943B1 (ko) 생물학적 물질 및 미생물의 보존과 보호를 위한 글리코펩티드 유도체
ES2274106T3 (es) Derivados de pirano como inhibidores tanto de ace como de nep.
DE60133654D1 (de) Arzneimittel enthaltend analgetische peptide
JP3240580B2 (ja) アスコルビル−ホスホリル−コレステロール
US7521477B2 (en) Vitamin C derivatives with peptide, preparation method thereof and composition comprising the same
EP0292923A3 (en) Piperidine compounds and pharmaceutical uses thereof
JPS6322524A (ja) 鎮痛剤として有用な環状及び架橋環状ソマトスタチンアナログ
KR19990044553A (ko) 펩티드 유도체
KR100458359B1 (ko) 메탈로 펩티다아제 억제활성을 갖는 포스폰산 유도체
CA2379508A1 (en) Biphasic skin composition comprising ascorbic acid, ceramides and betaglycane
BR0312972A (pt) Derivado de ácidos indolalcanóicos substituìdos e formulações contendo o mesmo para o uso no tratamento de complicações diabéticas
KR20240127500A (ko) 히알루론산 유도체-wkymvm 접합체 및 이의 용도
MX9603149A (es) Derivados de camptotecina.
SE0000782D0 (sv) Pharmaceutical formulation and its use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application